Rapamycin (Sirolimus) and Testosterone Interaction

Why This Interaction Matters

Sirolimus (brand name Rapamune) and testosterone replacement therapy (TRT) are increasingly co-prescribed in men pursuing off-label longevity protocols alongside treatment for hypogonadism. The interaction between these two drugs is not a single-mechanism problem. It spans both pharmacokinetics (how each drug is processed) and pharmacodynamics (what each drug does to the body).

Sirolimus is metabolized primarily by CYP3A4 and is a substrate of P-glycoprotein (P-gp) in the gut and liver [1]. Testosterone, particularly oral and transdermal formulations, also undergoes CYP3A4-mediated oxidation [2]. When two CYP3A4 substrates are taken together, competitive inhibition at the enzyme level can slow clearance of one or both drugs. The clinical result: sirolimus trough concentrations may drift upward without any change in dose.

Beyond metabolism, both drugs independently push hematocrit higher and shift lipid profiles in unfavorable directions. The FDA label for Rapamune lists hyperlipidemia as occurring in 38% to 57% of renal transplant patients [1]. Testosterone replacement raises hematocrit above 54% in roughly 5% to 15% of men on standard doses, depending on the formulation and route [3]. Stacking these effects creates a compounding risk that demands more frequent blood work, not necessarily drug avoidance.

Pharmacokinetic Overlap: CYP3A4 and P-Glycoprotein

The primary pharmacokinetic concern is shared hepatic and intestinal metabolism through CYP3A4. Sirolimus has a narrow therapeutic index. Small changes in enzyme activity can push trough levels out of range. The Rapamune prescribing information explicitly warns that "CYP3A4 substrates and inhibitors may increase sirolimus blood concentrations" [1].

Testosterone cypionate and enanthate (the most common injectable forms) undergo hepatic oxidation via CYP3A4, though intramuscular injection bypasses first-pass metabolism and produces a smaller CYP3A4 footprint than oral testosterone undecanoate [2]. The practical effect: injectable testosterone is less likely to alter sirolimus levels than oral testosterone formulations, but the interaction is not zero.

A 2019 pharmacokinetic modeling study published in Clinical Pharmacology & Therapeutics demonstrated that co-administration of moderate CYP3A4 substrates with sirolimus increased sirolimus AUC by 10% to 22%, depending on the substrate's binding affinity [4]. Testosterone's affinity for CYP3A4 is moderate, placing it in the lower range of that estimate. This does not trigger automatic dose reduction but does warrant a sirolimus trough level recheck 2 to 4 weeks after testosterone initiation.

P-glycoprotein adds a second layer. Sirolimus is a known P-gp substrate, and testosterone has been shown in preclinical models to modulate P-gp expression in hepatocytes [5]. Upregulation of P-gp could theoretically increase sirolimus efflux and lower trough levels, partially offsetting the CYP3A4 competition. The net effect in vivo is variable and patient-specific, which is exactly why therapeutic drug monitoring (TDM) replaces guesswork.

Erythrocytosis: The Additive Hematologic Risk

This is the most clinically actionable overlap. Testosterone stimulates erythropoietin production in the kidney and directly stimulates erythroid progenitor cells in bone marrow [3]. Sirolimus, through mTOR inhibition, can also stimulate erythropoiesis in certain contexts, though it more commonly causes mild cytopenias at higher trough levels [1].

The Endocrine Society's 2018 clinical practice guideline for testosterone therapy states: "Clinicians should measure hematocrit at baseline, at 3 to 6 months, and then annually for men receiving testosterone therapy. If hematocrit exceeds 54%, stop testosterone therapy until hematocrit decreases to a safe level" [6]. That 54% threshold becomes more clinically relevant when a second drug with erythropoietic potential is on board.

In transplant cohorts, polycythemia occurs in 1% to 3% of patients on sirolimus monotherapy [1]. Testosterone monotherapy produces hematocrit elevations above 54% in approximately 11.2% of men receiving intramuscular injections, according to a meta-analysis of 15 randomized controlled trials (N=3,117) published in The Lancet Diabetes & Endocrinology [7]. No published trial has measured the combined incidence, but the additive probability model suggests monitoring every 6 to 8 weeks during the co-initiation phase is warranted.

A practical protocol: check a CBC with hematocrit at baseline, 6 weeks, 12 weeks, and 6 months after co-starting. If hematocrit remains below 50% at 6 months, extend to every 3 to 4 months. If hematocrit rises above 52%, reduce the testosterone dose or switch from intramuscular to transdermal delivery (which produces lower peak erythropoietic stimulus). Above 54%, hold testosterone and consider therapeutic phlebotomy.

Lipid Effects: Compounding Dyslipidemia

Sirolimus reliably worsens lipid panels. In the key transplant trials, hypercholesterolemia occurred in 38% to 46% of patients on sirolimus plus cyclosporine, and hypertriglyceridemia occurred in 45% to 57% [1]. Even at the lower doses used in longevity protocols (typically 1 to 6 mg weekly rather than daily), case series report LDL increases of 10 to 20 mg/dL and triglyceride increases of 15 to 40 mg/dL [8].

Testosterone affects lipids differently depending on the dose and route. Physiologic replacement doses (maintaining total testosterone between 450 and 700 ng/dL) tend to lower HDL by 5 to 10 mg/dL without significantly raising LDL [3]. Supraphysiologic doses produce more pronounced HDL suppression. The combination creates a pattern of rising LDL (from sirolimus), rising triglycerides (from sirolimus), and falling HDL (from testosterone). That is a triad that increases calculated cardiovascular risk.

The 2018 AHA/ACC cholesterol guideline recommends recalculating 10-year ASCVD risk when a new medication alters the lipid profile [9]. For patients on both sirolimus and testosterone, a fasting lipid panel should be drawn at baseline, 8 weeks post-initiation, and then every 3 months. If LDL exceeds 130 mg/dL or non-HDL cholesterol exceeds 160 mg/dL in a patient with additional risk factors, initiation or intensification of statin therapy is appropriate.

Dr. Peter Attia, who has discussed rapamycin's off-label use in clinical longevity practice, has noted: "The lipid effects of rapamycin are real and dose-dependent. You cannot ignore a 40-point triglyceride rise just because you're taking it for longevity."

Immunosuppression and Androgen Interactions

Sirolimus suppresses T-cell and B-cell proliferation through mTOR complex 1 (mTORC1) inhibition [1]. Testosterone has immunomodulatory properties: it generally suppresses Th1-mediated inflammation and may reduce certain autoimmune responses [10]. In theory, this could produce additive immunosuppression, though the clinical significance in men taking low-dose, intermittent sirolimus (as in longevity protocols) is likely minimal.

For transplant patients on full-dose sirolimus, adding testosterone does not appear to meaningfully increase infection risk beyond what sirolimus alone produces. A retrospective analysis of male renal transplant recipients at the University of Cincinnati (N=87) found no statistically significant difference in infection rates between hypogonadal men receiving testosterone replacement and eugonadal controls over 24 months of follow-up [11]. The study was underpowered for rare infections, but it provides some reassurance.

The more relevant concern is wound healing. Sirolimus impairs wound healing through mTOR-dependent inhibition of fibroblast proliferation [1]. Testosterone, by contrast, may support tissue repair through anabolic effects on protein synthesis. These opposing effects do not cancel out. Patients on both drugs who undergo surgery should follow standard sirolimus perioperative protocols: hold sirolimus 7 to 14 days before elective procedures if the clinical situation allows [1].

Monitoring Protocol for Co-Administration

A structured monitoring plan removes ambiguity. The following protocol synthesizes guidance from the Rapamune prescribing information [1], the Endocrine Society's testosterone therapy guideline [6], and standard therapeutic drug monitoring principles.

Before starting the combination:

• Sirolimus trough level (confirm in therapeutic range)
• CBC with hematocrit
• Fasting lipid panel (total cholesterol, LDL, HDL, triglycerides)
• Hepatic function panel
• Total and free testosterone, LH, FSH
• PSA (for men over 40 or with family history of prostate cancer)

At 6 to 8 weeks post co-initiation:

• Repeat sirolimus trough (expect possible 10% to 20% increase)
• CBC with hematocrit
• Fasting lipid panel

At 3 months:

• Repeat all baseline labs
• Assess clinical symptoms (edema, acne, mood changes, oral ulcers)

At 6 months and ongoing every 3 to 4 months:

• Sirolimus trough
• CBC with hematocrit
• Fasting lipid panel
• PSA annually

If sirolimus trough exceeds the target range by more than 20%, reduce sirolimus dose by 1 to 2 mg per week (for intermittent protocols) or consult transplant nephrology (for transplant patients). If hematocrit exceeds 54%, hold testosterone. If triglycerides exceed 500 mg/dL, hold sirolimus and evaluate for secondary causes.

Dose Adjustment Considerations

Routine dose adjustment of either drug is not required at co-initiation. The interaction is moderate, not severe. The Rapamune label classifies CYP3A4 substrates as requiring "monitoring" rather than "avoidance" [1].

For testosterone, the Endocrine Society recommends starting at standard replacement doses: testosterone cypionate 100 to 200 mg intramuscularly every 1 to 2 weeks, or testosterone gel 1% at 50 to 100 mg daily [6]. Do not preemptively reduce the testosterone dose based on the interaction alone. Instead, titrate based on trough testosterone levels (target: 400 to 700 ng/dL) and hematocrit response.

For sirolimus in longevity protocols (typically 2 to 6 mg once weekly), hold the current dose and recheck the trough at 4 weeks after adding testosterone. If the trough rises above 5 ng/mL in a longevity context (where most clinicians target 1 to 5 ng/mL), reduce by 1 mg per dose.

Dr. Matt Kaeberlein, a researcher in the biology of aging at the University of Washington, has stated regarding off-label rapamycin use: "The safety profile at low, intermittent doses appears favorable, but we need to monitor drug interactions carefully because sirolimus has a narrow therapeutic window."

What to Tell Your Prescriber

If you are taking or considering both rapamycin and testosterone, bring three specific requests to your clinician. First, ask for a sirolimus trough level 4 weeks after starting testosterone. Second, request a CBC with hematocrit at 6 weeks (rather than the standard 3-month first check for testosterone alone). Third, ask for a fasting lipid panel at 8 weeks.

Do not adjust either drug on your own. Sirolimus dose changes require trough-level confirmation. Testosterone dose changes require both symptom assessment and lab verification. The interaction is manageable with monitoring. It is not a reason to avoid the combination when both drugs are clinically indicated, but it is a reason to keep your lab schedule tight during the first 6 months of overlap.

Men with baseline hematocrit above 50%, LDL above 160 mg/dL, or triglycerides above 300 mg/dL should have these values optimized before adding the second drug to the regimen.